Is CNBX Pharmaceuticals Inc. (CNBX) a Buy, Sell, or Hold?
CNBX Pharmaceuticals Inc.
PNK:CNBX
$0.01 USD
$0.0 (33.33%)
- Volume
- 10.1K
- Average Volume
- 90.3K
- Market Capitalization
- $311.11K
- P/E Ratio
- -0.26
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $0.02
- Year Low
- $0.01
- Payout Ratio
- $0.00
- Current Ratio
- $0.03
Industry, Sector & symbol
| Stock Exchange | Other OTC |
| CEO | Mr. Eyal Barad |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CNBX |
| CUSIP | 13764M100 |
| CIK | 0001343009 |
| Web | https://www.cnbxpharma.com |
| Phone | 877 424 2429 |
| Currency | USD |
| Employees | 2 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.53 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.03 |
| Quick Ratio | 0.03 |
| Cash Ratio | 0.03 |
Sales & Book Value
| Annual Sales | $130.07K |
| Price / Sales | 1.26 |
| Cash Flow | -0.01 |
| Price / Cash Flow | -1.76 |
| Price / Book | -0.13 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.023 |
| Trailing P/E Ratio | -0.26 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-695.2K |
| Net Margin | -487.86% |
| Pretax Margin | -464.85% |
| Return on Equity | 54.15% |
| Return on Assets | -1509.70% |
Financials Score
| AltmanZ Score | -514.66 |
| Piotroski Score | 3.00 |
| Working Capital | -2.45M |
| Total Assets | 80.03K |
| Ebit | -1.1M |
| Market Cap | 311.11K |
| Total Liabilities | 2.53M |
Poll Results
About CNBX Pharmaceuticals Inc. (PNK:CNBX) Stock
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivit ... y test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
2021-10-19 09:41:00
TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19 th.
2021-10-18 12:49:41
Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients. These patent applications are now part of the Cannabics growing IP portfolio comprising of eight patent families with five granted patents and 19 pending applications.
2021-10-18 09:05:00
TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
2021-09-30 09:25:00
TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated its corporate image with a new logo and a new website.
2021-09-22 09:15:00
TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston.
Frequently Asked Questions
-
What is the current CNBX Pharmaceuticals Inc. (CNBX) stock price?
-
CNBX Pharmaceuticals Inc.(PNK:CNBX) stock price is $0.01 in the last trading session. During the trading session, CNBX stock reached the peak price of $0.02 while $0.0075 was the lowest point it dropped to. The percentage change in CNBX stock occurred in the recent session was 33.33% while the dollar amount for the price change in CNBX stock was $0.0.
-
CNBX's industry and sector of operation?
-
The PNK listed CNBX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CNBX?
-
Dr. Ilya Reznik M.D. | Head of Neuropsychiatry Development
Mr. Eyal Barad | Co-Founder, Chief Executive Officer & Director
Mr. Gabriel Yariv | President, Chief Operating Officer & Executive Chairman
Mr. Uri Ben-Or C.P.A., CPA, M.B.A., MBA | Chief Financial Officer
Noam Permont | Vice President of Public Relations & Investor Relations -
How many employees does CNBX have?
-
Number of CNBX employees currently stands at 2. CNBX operates from #3 Bethesda Metro Center, Bethesda, MD 20814, US.
-
Link for CNBX official website?
-
Official Website of CNBX is: https://www.cnbxpharma.com
-
How do I contact CNBX?
-
CNBX could be contacted at phone #877 424 2429 and can also be accessed through its website. CNBX operates from #3 Bethesda Metro Center, Bethesda, MD 20814, US.
-
How many shares of CNBX are traded daily?
-
The average number of CNBX shares traded daily for last 3 months was 90.3K.
-
What is the market cap of CNBX currently?
-
The market value of CNBX currently stands at $311.11K with its latest stock price at $0.01